secwatch.observer — SEC 8-K summary
======================================

Issuer:     iSpecimen Inc. (ISPC)
CIK:        0001558569
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001213900-24-111290
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iSpecimen names Yuying Liang CFO, unveils plan to expand cancer biospecimen procurement
--------------------------------------------------------------------------------

- Appointed Yuying Liang as CFO effective Dec 13, 2024; monthly fee of $25k under engagement with his professional corp.
- Strategic 2025 initiatives focus on procuring high-demand cancer biospecimens through expanded partnerships.
- Plans to establish referral program with international genomic sequencing partner; iSpecimen to be preferred provider.
- Targeting new partnerships with U.S. cancer centers for domestic blood products, with 2025 launch.
- Will expand portfolio with remnant biofluid offerings from recently partnered sites, including diagnostic codes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1558569/000121390024111290/0001213900-24-111290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1558569/000121390024111290/ea0225487-8k_ispecimen.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-111290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer